Sandbox Rim: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 1: | Line 1: | ||
==FIRE: Focused Initial Rapid Evaluation== | ==FIRE: Focused Initial Rapid Evaluation== | ||
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention. | A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention based on the 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction.<ref name="pmid22809746">{{cite journal| author=Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE et al.| title=2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=J Am Coll Cardiol | year= 2012 | volume= 60 | issue= 7 | pages= 645-81 | pmid=22809746 | doi=10.1016/j.jacc.2012.06.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22809746 }} </ref> | ||
<span style="font-size:85%">Boxes in the red color signify that an urgent management is needed.</span> | <span style="font-size:85%">Boxes in the red color signify that an urgent management is needed.</span> | ||
Line 66: | Line 66: | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| C07 | | C08 |!| C07= ECG and biomarkers are both negative | C08= At least one (ECG or biomarkers) is positive}} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| C07 | | C08 |!| C07= ECG and biomarkers are both negative | C08= At least one (ECG or biomarkers) is positive}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| |!| | | |!| |!| }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| |!| | | |!| |!| }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!|C09 | | | C10 | | | C09= <div style="float: left; text-align: left; width: 25em; padding:1em;"> | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!|C09 | | | C10 | | | C09= <div style="float: left; text-align: left; width: 25em; padding:1em;">[[Chest pain resident survival guide#Complete Diagnostic Approach|Proceed to complete diagnostic approach of chest pain to rule out differential diagnoses]]</div>| C10=<div style="float: left; text-align: left; width: 25em; padding:1em;">'''Calculate the risk of future adverse clinical outcomes:'''<br> | ||
❑ [[TIMI risk score|<span style="color:white;">Thrombolysis in Myocardial Infarction (TIMI) risk score</span>]], OR | ❑ [[TIMI risk score|<span style="color:white;">Thrombolysis in Myocardial Infarction (TIMI) risk score</span>]], OR | ||
❑ [[GRACE score|<span style="color:white;">GRACE score</span>]] </div> | ❑ [[GRACE score|<span style="color:white;">GRACE score</span>]] </div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|-|^|.| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|-|^|.| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | D01 | | D02 | | D03 | |D01=<div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Proceed to [[angiography|<span style="color:white;">angiography </span>]]'''<br></div> | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | D01 | | D02 | | D03 | |D01=<div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Proceed to [[angiography|<span style="color:white;">angiography </span>]]'''<br></div> | ||
Line 148: | Line 148: | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | G01 | | G02 | G01= Yes| G02= No}} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | G01 | | G02 | G01= Yes| G02= No}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | |!| | | |!| }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | |!| | | |!| }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | H01 | | H02 | H01= | H02= }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | H01 | | H02 | H01= <div style="float: left; text-align: left; width: 20em; padding:1em;"> ❑ Perform an [[angiography]]<br> | ||
----- | |||
Administer upstream antiplatelet agent:<br> | |||
❑ [[P2Y12]] receptor inhibitors <br> | |||
:❑ [[Clopidogrel]]<br> | |||
::❑ Loading dose (600 mg)<br> | |||
::❑ Maintenance dose (75 mg), or<br> | |||
:❑ [[Ticagrelor]]<br> | |||
::❑ Loading dose (180 mg)<br> | |||
::❑ Maintenance dose (90 mg twice daily), or<br> | |||
❑ IV [[GP IIb/IIIa]] inhibitors <br> | |||
:❑ [[Eptifibatide]]<br> | |||
::❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes<br> | |||
::❑ Maintenance dose 2 mcg/kg/min, or <br> | |||
:❑ [[Tirofiban]] <br> | |||
::❑ Loading dose 25 mcg/kg<br> | |||
::❑ Maintenance dose 0.15 mcg/kg/min<br></div> | |||
| H02= ❑ Perform a [[stress test]] }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | |,|-|-|^|.|}} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | |,|-|-|^|.|}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | I01 | | I02 | I01= | I02= }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | I01 | | I02 | I01= '''Low risk on stress test'''| I02= '''High risk on stress test'''}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | |!| | | |!| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | |!| | | |!| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | |!| | | J01 | J01= }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | |!| | | J01 | J01= ❑ Perform an [[angiography]]}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | K01 | | | | | K01= }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | K01 | | | | | K01= <div style="float: left; text-align: left; width: 20em; padding:1em;"> ❑ Continue [[aspirin]] for life <br> ❑ Continue [[P2Y12]] receptor inhibitors up to 12 months<br> | ||
:❑ [[Clopidogrel]] (75 mg once a day), or<br> | |||
:❑ [[Ticagrelor]] (90 mg twice a day)<br> | |||
❑ Discontinue [[GP IIb/IIIa]] inhibitors <br> | |||
❑ Continue [[antithrombotic]] therapy:<br> | |||
:❑ [[UFH]] for 48 hours, or<br> | |||
:❑ [[Enoxaparin]] for up to 8 days, or <br> | |||
:❑ [[Fondaparinux]] for up to 8 days</div>}} | |||
{{familytree/end}} | {{familytree/end}} |
Revision as of 02:39, 7 April 2015
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention based on the 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction.[1]
Boxes in the red color signify that an urgent management is needed.
Identify cardinal findings of unstable angina/ NSTEMI : ❑ Chest pain or chest discomfort
❑ Characteristic ECG changes consistent with unstable angina/ NSTEMI
| |||||||||||||||||||||||||||
Rule out life threatening alternative diagnoses: ❑ Aortic dissection (suggestive findings: vomiting, subcutaneous emphysema) | |||||||||||||||||||||||||||
Begin initial treatment: ❑ Administer aspirin (I-A)
❑ Administer 2-4 L/min oxygen via nasal cannula when saturation <90%
❑ Administer beta-blockers (unless contraindicated) and titrate to the heart rate and blood pressure
❑ Administer sublingual nitroglycerin 0.4 mg every 5 minutes for a total of 3 doses
❑ Administer 80 mg atorvastatin | |||||||||||||||||||||||||||
Does the patient have any of the following indications that require immediate angiography and revascularization ?
❑ Hemodynamic instability or cardiogenic shock | |||||||||||||||||||||||||||
YES | NO | ||||||||||||||||||||||||||
Does the patient have negative ECG findings AND negative biomarkers? | |||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||
Repeat ECG and biomarkers within next 6 hours and 12 hours | |||||||||||||||||||||||||||
ECG and biomarkers are both negative | At least one (ECG or biomarkers) is positive | ||||||||||||||||||||||||||
Calculate the risk of future adverse clinical outcomes: ❑ Thrombolysis in Myocardial Infarction (TIMI) risk score, OR ❑ GRACE score | |||||||||||||||||||||||||||
Proceed to angiography | Intermediate or high risk Initial invasive strategy | Low risk Initial conservative strategy | |||||||||||||||||||||||||
Administer ONE of the following antiplatelet agents (before or at the time of PCI):
Prasugrel is contraindicated in case of prior history of strokes or TIAs, active pathological bleeding, age ≥75 years, when urgent coronary artery bypass graft surgery (CABG) is likely, body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding
Administer ONE of the following anticoagulant therapy:
| Administer ONE of the following antiplatelet agents (before OR at the time of PCI) Before PCI
OR
OR
| Administer ONE of the following antiplatelet agents: ❑ Clopidogrel (I-B)
❑ Ticagrelor (I-B)
| |||||||||||||||||||||||||
❑ Perform an angiography | Does the patient experience any of the following? ❑ Recurrence of symptoms | ||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||
❑ Perform an angiography Administer upstream antiplatelet agent:
❑ IV GP IIb/IIIa inhibitors
| ❑ Perform a stress test | ||||||||||||||||||||||||||
Low risk on stress test | High risk on stress test | ||||||||||||||||||||||||||
❑ Perform an angiography | |||||||||||||||||||||||||||
❑ Continue aspirin for life ❑ Continue P2Y12 receptor inhibitors up to 12 months
❑ Discontinue GP IIb/IIIa inhibitors
| |||||||||||||||||||||||||||
- ↑ Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE; et al. (2012). "2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 60 (7): 645–81. doi:10.1016/j.jacc.2012.06.004. PMID 22809746.
- ↑ "ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI".